Results 161 to 170 of about 22,884 (253)

Navigating market access after conditional reimbursement: a communication roadmap for disinvesting orphan drugs. [PDF]

Int J Technol Assess Health Care
Abdallah K, Blonda A, Godman B, Huys I, Claes K, Denier Y, Simoens S.   +6 more
europepmc   +1 more source

Correction: Immunometabolic remodeling: new perspectives and strategies for liver transplantation. [PDF]

Front Immunol
Wang L, Sheng X, Shi G, Li Y, Wang D, Wang W, Mi C, Wang S, Du Y, Yang H.   +9 more
europepmc   +1 more source

The imperative for national legislation on rare diseases in China: A policy review and call to action. [PDF]

Intractable Rare Dis Res
Li Y, Liu Z, Huang R, Liu Y.
europepmc   +1 more source

Propolis Flavonoids Ameliorate Chronic Osteomyelitis in a Rat Model by Modulating TAZ‐Regulated Treg/Th17 Balance

Immunity, Inflammation and Disease, Volume 14, Issue 6, June 2026.
This diagram illustrates the mechanism by which Propolis Flavonoids (PF) ameliorate Chronic Osteomyelitis (COM). PF upregulates the transcriptional coactivator TAZ, which is suppressed in COM. Elevated TAZ restores Treg/Th17 homeostasis by promoting the Th17‐master regulator RORγt while suppressing the Treg‐specific transcription factor FOXP3.
Yujie Wang, Chaozhu Zhang, Zeyang He, Liqiang Li   +3 more
wiley   +1 more source

Addressing challenges along the 'access cascade' for new TB regimens. [PDF]

IJTLD Open
Servello J, de Colombani P, Dall'Olio L, Gargioni G, Raviglione MCB.   +4 more
europepmc   +1 more source

Genome‐Wide In Silico Analysis of the Type VI Secretion System (T6SS) Within the Morganella Genus

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
▪ Species‐specific T6SS patterns among Morganella genus (M. morganii and M. sibonii). ▪ Only one‐third of M. morganii isolates haboured a T6SS. ▪ All M. sibonii possess four T6SS clusters. ▪ M. sibonii exhibited a wide diversity of effectors compared to M. morganii.
Mathilde Duque, Aymeric Jacquemin, Delphine Girlich, Rémy A. Bonnin, Laurent Dortet   +4 more
wiley   +1 more source

Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: a focused review for orphan drug (Tofersen). [PDF]

Orphanet J Rare Dis
Kumar A, Shukla S, Rai A, Pathak P, Narayan KP.   +4 more
europepmc   +1 more source

Progress in Natural Products Target Discovery Technology

MedComm, Volume 7, Issue 6, June 2026.
Here, we provide a comprehensive overview of current technologies and recent advancements in therapeutic target discovery for natural products. By systematically synthesizing the principles, methodologies, and practical applications of existing experimental and computational strategies, this work provides a more actionable reference framework for ...
Qiyuan Pan, Xiao Yuan, Jinmei Jin, Xin Luan, Cheng Luo, Hongzhuan Chen, Weidong Zhang, Hao Zhang   +7 more
wiley   +1 more source

Multi-criteria decision analysis of value evaluation of rare disease medical insurance drugs in China. [PDF]

BMC Public Health
Chen K, Duan Y, Cao Z, Wu Y, Wang J, Jiang B, Gu R.   +6 more
europepmc   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source